|
www.aurobindo.com |
|
|
|
Aurobindo
receives USFDA
Approval for its Ciprofloxacin |
|
|
Aurobindo is pleased to announce
that US FDA has approved its Ciprofloxacin
tablets in strengths 250, 500 and 750mg.
Ciprofloxacin belongs to the class of
floroquinolones.
Ciprofloxacin
is the generic international name for the
synthetic microbicide
manufactured and sold by
Bayer Pharmaceutical under the brand
names Cipro®, Ciproxin® and
Ciprobay® |
|
Ciprofloxacin is considered a
yardstick with which the other quinolones
efficacies are measured against.
Ciprofloxacin is a
broad-spectrum antibiotic that is
active against both
Gram-positive and
Gram-negative bacteria. |
|
It is used in
lower respiratory infections (pneumonias),
urinary tract infections,
STDs,
septicemias,
Legionellosis and in some atypicals. |
|
Ciprofloxacin enjoys a market of
over $230 mio in the USA. |
|
About Aurobindo Pharma Limited: |
|
Aurobindo Pharma Limited
(www.aurobindo.com), headquartered at Hyderabad,
India, manufactures generic pharmaceuticals and
active pharmaceutical ingredients. The company
has received approvals for most of the targeted
API and formulation facilities from leading
regulatory agencies like US FDA, UK MHRA, WHO,
Health Canada, MCC South Africa. The company’s
robust product portfolio is spread over 6 major
therapeutic/product areas encompassing
Antibiotics, Anti-Retrovirals, CVS, CNS,
Gastroenterologicals, and Anti-Allergics. The
formulation portfolio is built on six technology
platforms such as immediate release generics,
SR/CR generics, Orally disintegrating/Mouth
dissolving generics, Combination products,
Sterile/Lyophilized generics and Liquids/Dry
syrups.
Aurobindo has filed over 100 DMFs
and 79 ANDAs for the USA market alone in
addition to filings in other countries. The pace
of filings is matched by rapid product approvals
from various markets. Till date Aurobindo
received 40 ANDA approvals (both final and
tentative) from US alone. Aurobindo operates in
over 100 countries and markets over 180 APIs and
250 formulations |
For further information,
please contact:
Investor Relations
Aurobindo Pharma Limited
Plot # 2, Maitri Vihar | Ameerpet
Hyderabad - 500 038 |India
Phone (Board): +91 40 6672 5000
Mobile 0 98486 67906
Email : ir@aurobindo.com |
|
|
|
|
|
|
|
|
|
PRESS
ROOM
